A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 117997 Moscow, Russia.
Int J Mol Sci. 2022 Jan 1;23(1):483. doi: 10.3390/ijms23010483.
Uremic retention solutes are the compounds that accumulate in the blood when kidney excretory function is impaired. Some of these compounds are toxic at high concentrations and are usually known as "uremic toxins". The cumulative detrimental effect of uremic toxins results in numerous health problems and eventually mortality during acute or chronic uremia, especially in end-stage renal disease. More than 100 different solutes increase during uremia; however, the exact origin for most of them is still debatable. There are three main sources for such compounds: exogenous ones are consumed with food, whereas endogenous ones are produced by the host metabolism or by symbiotic microbiota metabolism. In this article, we identify uremic retention solutes presumably of gut microbiota origin. We used database analysis to obtain data on the enzymatic reactions in bacteria and human organisms that potentially yield uremic retention solutes and hence to determine what toxins could be synthesized in bacteria residing in the human gut. We selected biochemical pathways resulting in uremic retention solutes synthesis related to specific bacterial strains and revealed links between toxin concentration in uremia and the proportion of different bacteria species which can synthesize the toxin. The detected bacterial species essential for the synthesis of uremic retention solutes were then verified using the Human Microbiome Project database. Moreover, we defined the relative abundance of human toxin-generating enzymes as well as the possibility of the synthesis of a particular toxin by the human metabolism. Our study presents a novel bioinformatics approach for the elucidation of the origin of both uremic retention solutes and uremic toxins and for searching for the most likely human microbiome producers of toxins that can be targeted and used for the therapy of adverse consequences of uremia.
尿毒症潴留溶质是指当肾脏排泄功能受损时,在血液中积累的化合物。其中一些化合物在高浓度时具有毒性,通常被称为“尿毒症毒素”。尿毒症毒素的累积有害影响导致急性或慢性尿毒症期间出现许多健康问题,最终导致死亡,尤其是在终末期肾病中。在尿毒症期间,有超过 100 种不同的溶质增加;然而,它们的大部分确切来源仍存在争议。这些化合物有三个主要来源:外源性的是通过食物摄入的,而内源性的是由宿主代谢或共生微生物群代谢产生的。在本文中,我们确定了可能源自肠道微生物群的尿毒症潴留溶质。我们使用数据库分析获得了有关细菌和人体中潜在产生尿毒症潴留溶质的酶促反应的数据,从而确定哪些毒素可以在居住在人体肠道中的细菌中合成。我们选择了与特定细菌菌株相关的导致尿毒症潴留溶质合成的生化途径,并揭示了尿毒症中毒素浓度与能够合成毒素的不同细菌种类比例之间的联系。然后使用人类微生物组计划数据库验证了检测到的对尿毒症潴留溶质合成至关重要的细菌物种。此外,我们定义了产生尿毒症潴留溶质的人类毒素生成酶的相对丰度以及人类代谢物合成特定毒素的可能性。我们的研究提出了一种新的生物信息学方法,用于阐明尿毒症潴留溶质和尿毒症毒素的起源,并寻找最有可能产生可靶向用于治疗尿毒症不良后果的毒素的人类微生物组生产者。